Nicholas Johnson is a Clinical Trials Statistician at Imperial Clinical Trials Unit (ICTU), School of Public Health with over 6 years experience in clinical trials.
Whilst primarily part of the Cardiovascular/Respiratory trial team, he has worked on studies across a number of therapeutic areas. He has also had experience in Phase 1 Pharmacokinetic (PK) analysis. Current studies include; HOPE-HF, DeVENT, MALIBO and RIO whilst past studies include AVATAR-AF, Endobarrier and SERCA-LVAD.
Nicholas completed his BSc in Statistics and Computing from the Open University in 2011 and subsequently obtained an MSc (Merit) in Statistics from the University of Kent in 2013.
A keen runner and cat-lover, Nicholas has been with ICTU since October 2015.
et al., 2020, Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL, Gene Therapy, ISSN:0969-7128
et al., 2020, Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomized trials, Bmc Medicine, Vol:18, ISSN:1741-7015
et al., 2019, Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation (AVATAR-AF): design and rationale, American Heart Journal, Vol:214, ISSN:0002-8703, Pages:36-45
et al., 2019, Combined GLP-1, oxyntomodulin, and peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized single-blinded placebo controlled study, Diabetes Care, Vol:42, ISSN:0149-5992, Pages:1446-1453
Johnson NA, Sasikaran T, 2019, AVATAR-AF: Getting to the heart of data management for analysis (5 simple rules to follow to ensure data integrity), BMC